Bill Fleming and David Browning join board of the not-for-profit membership organisation supporting UK's life sciences companies, corporate partners and investors
Bill Fleming, Chairman of the Board
OBN, the organisation that brings together UK life science companies, has announced a promotion and a new appointment. Bill Fleming has been internally recruited from Non-Executive Director to Chairman of the Board replacing Sally Waterman, with David Browning filling the newly open Non-Executive Director position.
Fleming served as a Non-Executive Director from April 2017 and is member of OBN’s Investment and Tax Special Interest Group. John Harris, CEO of OBN said Fleming will use his “in-depth knowledge of OBN” to “take on a more active role in providing leadership.”
The outside recruit Browning is currently the CEO of Oxford Cancer Biomarkers who are members of OBN and has 37 years of experience in healthcare innovation.
Commenting on the appointment, Browning said he has “been an advocate of OBN for many years”.
Both John Harris and Sally Waterman say they look forward to seeing the results of the experience these two will bring to the board.